Search results
Cardiovascular Risk in Asian Immigrants in the UK
Added:
2 months ago
Systematic Review
Added:
2 months ago
ACC.26 – Dr Michael McConnell (Stanford Health Care, Stanford, CA, US) joins us to discuss findings from a prospective, multicentre clinical trial evaluating whether artificial intelligence analysis of retinal images can identify patients at elevated atherosclerotic cardiovascular risk.Findings showed strong sensitivity and specificity in identifying those at risk of ASCVD in a diverse study…
View more
Added:
2 months ago
ACC 2026 — Prof Divaka Perera (Guy's & St Thomas' Hospital and King's College London, UK) joins us to discuss findings from the CHIP-BCIS3 trial, examining the role of percutaneous left ventricular unloading in patients undergoing high-risk coronary intervention.This phase 3 randomised controlled trial enrolled 300 patients with severe left ventricular dysfunction and extensive coronary artery…
View more
Added:
3 months ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19…
View more
Added:
1 year ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical…
View more
Added:
8 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type…
View more
Added:
1 year ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global…
View more
Hospital Frailty Risk Score in Heart Failure
Added:
2 years ago
Case Report
GLP-1 RAs in T2D and Established or High-risk ASCVD
Added:
1 year ago
Expert Opinion
Risk Prediction of CVD in the Asia-Pacific Region
Added:
1 year ago
Original Research